

TO ALL STOCK EXCHANGES

**BSE LIMITED
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
NEW YORK STOCK EXCHANGE**

May 02, 2025

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

It is hereby informed that BASE Life Sciences A/S, a step-down wholly owned subsidiary of Infosys Limited has transferred its entire shareholding in BASE Life Sciences Inc., a step-down wholly owned subsidiary of Infosys Limited to Infosys BPM UK Limited, a step-down wholly owned subsidiary of Infosys Limited effective May 1, 2025.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are hereby enclosed as **Annexure-A**.

This is for your information and records.

This will also be hosted on the Company's website, at www.infosys.com

Yours sincerely,
For **Infosys Limited**

A.G.S. Manikantha
Company Secretary
Membership No: 21918

Annexure-A

Disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Details and reasons for restructuring;	Transfer of entire shareholding by BASE Life Sciences Denmark A/S in BASE Life Sciences Inc. to Infosys BPM UK Limited, effective May 1, 2025. The inter-group transfer is undertaken to enhance operational efficiency, expand the market presence and streamline business operations.
Quantitative and/ or qualitative effect of restructuring	Enhancing operational efficiency, expansion of market presence and streamlining of business operations
Details of benefit, if any, to the promoter/promoter group/group companies from such proposed restructuring	Not Applicable
Brief details of change in shareholding pattern (if any) of all entities	Internal restructuring through transfer of entire shareholding by BASE Life Sciences A/S in BASE Life Sciences Inc. to Infosys BPM UK Limited. Consequent to this transfer, the shareholding pattern of BASE Life Science Inc. is as follows: Infosys BPM UK Limited: 100%